Physician profile
Arjun Vaid
NPI 1467617803
$4,361.77
in general payments reported to CMS, 2019-2025
27 companies · $590 in 2025
The $590 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $152 · 2021: $776 · 2022: $889 · 2023: $548 · 2024: $715 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787 · Education: $65.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,786.70 |
| Education | $65.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,834.08 | 2019-2025 | Rinvoq, Linzess, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $632.33 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $418.00 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $260.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.82 | 2019-2024 | Xifaxan |
| Celgene Corporation | $121.22 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $113.79 | 2021 | |
| Lilly USA, LLC | $80.95 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $76.20 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $70.99 | 2019-2021 | |
| Ardelyx, INC. | $68.95 | 2022-2023 | Ibsrela |
| Genzyme Corporation | $54.13 | 2022-2025 | |
| Celltrion USA INC. | $53.68 | 2024-2025 | Zymfentra, Vegzelma |
| Organon LLC | $48.73 | 2024 | |
| Ferring Pharmaceuticals INC. | $40.79 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $36.61 | 2019 | |
| Alnylam Pharmaceuticals INC. | $35.12 | 2025 | Givlaari |
| Echosens North America, INC. | $35.00 | 2023 | Fibroscan |
| Amgen INC. | $32.65 | 2023 | Avsola, Amjevita |
| Redhill Biopharma INC. | $32.18 | 2021 | |
| Fresenius Kabi USA, LLC | $28.34 | 2023 | |
| Qol Medical, LLC | $20.51 | 2019 | |
| Ucb, INC. | $20.38 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.89 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $17.74 | 2023 | Linzess |
| Enterra Medical, INC. | $17.30 | 2023 | |
| Intercept Pharmaceuticals, INC. | $16.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Vaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.